Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature Medicine 11, 822 - 824 (2005)
doi:10.1038/nm0805-822
TZDs and diabetes: testing the waters
Clay F Semenkovich1
- The author is in the Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis, Missouri 63110, USA. e-mail: csemenko@wustl.edu
Abstract
The use of thiazolidinediones, drugs for type 2 diabetes that may also be useful for other chronic inflammatory disorders, is limited by fluid retention. Research in mice identifies a mechanism for this side effect and introduces a potential remedy (pages 861–866).
Many individuals with type 2 diabetes find that taking their medications introduces new medical problems into their lives. Thiazolidinediones (TZDs) enhance insulin sensitivity, lower blood glucose and suppress inflammation—but they can also cause life-threatening fluid retention and edema.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Insights into PPARγ from structures with endogenous and covalently bound ligandsNature Structural & Molecular Biology News and Views (01 Sep 2008)
The ABCs of β-cell dysfunction in type 2 diabetesNature Medicine News and Views (01 Mar 2007)
See all 3 matches for News And ViewsRESEARCH
Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorptionNature Medicine Article (01 Aug 2005)
Beyond the classic angiotensin-receptor-blocker profileNature Clinical Practice Cardiovascular Medicine Article (01 Jul 2008)
See all 8 matches for Research